Please login to the form below

Not currently logged in
Email:
Password:

Zykadia

This page shows the latest Zykadia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

Xalkori is for now keeping one step ahead of rival treatments, such as Novartis’Zykadia, which gained NICE approval for use in ALK+ patients in January, and Roche’s Alecensa, which

Latest news

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    Alecensa saw sales double to reach around $385m in 2017, and its ascendency also seems to have taken its toll on Novartis’second-generation drug Zykadia (ceritinib). ... After recording sales of $91m in 2016, Zykadia’s growth seems to have stalled

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    That allows Roche’s drug to take on Pfizer’s drug - as well as Novartis’ALK inhibitor Zykadia (ceritinib) which was approved for first-line use in the US and Europe ... Of the two new challengers, Alecensa seems to be gaining ground the fastest,

  • Novartis gets first-line approval for Xalkori challenger in EU Novartis gets first-line approval for Xalkori challenger in EU

    Novartis gets first-line approval for Xalkori challenger in EU. Zykadia showed a 45% reduction in the risk of disease progression compared to chemo. ... Novartis won US approval for first-line use of Zykadia on the back of those trial data last month.

  • Novartis' Zykadia claims US approval for first-line lung cancer Novartis' Zykadia claims US approval for first-line lung cancer

    Novartis' Zykadia claims US approval for first-line lung cancer. The Swiss pharma giant’s drug also receives CHMP positive opinion. ... The FDA has said Novartis' Zykadia can be used as a first-line treatment option for some patients with non-small

  • Novartis' Zykadia prepped to take on Xalkori in Europe Novartis' Zykadia prepped to take on Xalkori in Europe

    Novartis' Zykadia prepped to take on Xalkori in Europe. The Swiss pharma giant’s drug will treat ALK-positive NSCLC patients. ... More patients in Europe should be eligible for treatment with Novartis' Zykadia after the EMA's advisory committee backed

More from news
Approximately 12 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination with BMS's PD-1 immune checkpoint inhibitor nivolumab [Opdivo]. ... Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics